AI
The technology uses heart rate variability measurements to assess the severity of sepsis in ED patients.
The solution screens for plus disease, which is associated with severe ROP.
Individuals are also less likely to trust AI-suggested interventions than those recommended by humans.
Also, Lunit has received Taiwan's approval for its AI mammography solution.
The AI model still has a modest prediction accuracy and is slated for a wider clinical trial soon.
It will use its fresh funds to complete a multi-site validation study across eight Asia-Pacific markets.
This comes after it launched its CDI tool called DxPrime in June.
According to the World Health Organization, breast cancer survival rates vary significantly between different countries.
One of the projects will develop a digital navigator to support people with chronic conditions.
It will be used to accelerate collaborations with pharmaceutical firms.